Medical Oncology

Uzm. Dr. Safa Can Efil

Doctor and researcher Ankara Bilkent Şehir Hastanesi Ankara
Lung NeoplasmsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Lung Neoplasms 6 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Carcinoma, Non-Small-Cell Lung 2 publications
  • Breast Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionAnkara Bilkent Şehir Hastanesisaglik.gov.trFrom source
  • Area of workLung NeoplasmsExtracted from 6 publications · Model version —From source
  • Publications36 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0001-9586-2858ORCIDFrom source
  • Last synchronised5 November 2026 07:23https://ankarasehir.saglik.gov.tr/TR-331078/tibbi-onkoloji-klinigi-doktorlarimiz.html#safa-can-efilsaglik.gov.tr

Scientific work

Publications on Lung Neoplasms

36 publications

  1. Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study

    Research Square, 2026

    DOI 10.21203/rs.3.rs-11204389/v1 Open-access full textSource: OpenAlex

  2. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000610 PMID 42267536 Source: OpenAlex

  3. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

    Cancers, 2026

    DOI 10.3390/cancers18132127 PMID 42449669 Open-access full textSource: OpenAlex

  4. Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16664-1 Open-access full textSource: OpenAlex

  5. Feasibility and Prognostic Value of an Ovarian NAR-like Score in Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166266 PMID 42652669 Open-access full textSource: ORCID

  6. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis

    The oncologist, 2026

    DOI 10.1093/oncolo/oyag092 PMID 41838398 Open-access full textSource: ORCID

  7. Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study

    Future Oncology, 2026

    DOI 10.1080/14796694.2026.2622299 PMID 41607196 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  8. Effects of Neoadjuvant Chemotherapy Treatment on Perioperative Outcomes Following Radical Cystectomy

    The New Journal of Urology, 2026

    DOI 10.33719/nju1831536 Open-access full textSource: ORCID

  9. Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors

    2026

    DOI 10.20944/preprints202606.1063.v1 Open-access full textSource: ORCID

  10. Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors

    Current Oncology, 2026

    DOI 10.3390/curroncol33100590 PMID 42930157 Open-access full textSource: OpenAlex

View all 36 publications